[Funding alert] Paris-based Cure51 Secures €15 Million in Seed Funding

Sofinnova Partners led this startup funding round. Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, the CEO and co-founder of Datadog, were among the other investors.

With the help of the funds, it will be able to establish a distinctive cohort and investigate the biological mechanisms that allow some cancer patients to live a long life even while their disease is extremely aggressive.

Read also - Prague-based Flowpay Secures Over €2 Million in Seed Funding

By revealing these processes, the business aims to offer novel insights for precision medicine and therapeutic target development, empowering each patient to become an extraordinary survivor. The innovative analytical methods and the solid alliance the company has built with top oncology facilities across the globe are essential to this project.

Simon Turner, Partner at Sofinnova Partners said, “Looking at ‘mechanisms of exceptional survival’ is not a new concept, but Cure51 has taken this to a whole new level in terms of the scale of the endeavor plus leveraging the latest in analytical techniques, Cure51’s strong clinical network and ambitious team make this an investment we’re thrilled to support.”

Joanna Soroka, PhD, Principal at Hitachi Ventures GmbH said, “Modern AI models require world class datasets to uncover novel biology and discover transformative medicines, and this is what Cure51 is uniquely creating for cancer patients,”.

Nicolas Wolikow, Co-founder, and Chief Executive Officer of Cure51 said, “This funding marks a pivotal moment in Cure51’s journey, but more importantly, in the path towards curing cancer,”.

Simon Istolainen, Cure51 Co-founder and Chief Strategy and Scientific Network Officer said, “With this support, we are on our way to unlocking survival mechanisms and ultimately, saving countless lives,”.

It's proprietary partnership-based data collection system makes it possible to build a distinctive multimodal and multiomics Outliers database. Using its computational modeling-powered discovery platform.

In order to develop first-in-class treatments, Cure51 seeks to uncover the molecular mechanisms underlying this remarkable longevity through the identification and validation of targets that potentially influence these interactions.

About Cure51

Nicolas Wolikow and Simon Istolainen established Cure51 in March 2022. It is the great contribution in paris startup ecosystem. with the help of seasoned businesspeople and four internationally recognized cancer centers: the Gustave Roussy Institute (IGR, Paris, France); the Leon Bérard Center (CLB, Lyon, France); Charité Universitätsmedizin (Berlin, Germany); Milan, Italy; and Vall d'Hebron (VHIO, Barcelona, Spain).

Read also -  Valencia-based Imperia Secures €3 Million in Funding

Their goal at Cure51 is to build the first global database of cancer survivors so that they can take advantage of their unique biological characteristics and develop novel therapeutics for cancer treatment.